Sulbactam

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Meropenem and Sulbactam is a potent ultra-broad-spectrum parenteral carbapenem-beta-lactamase inhibitor combination. Meropenem resists degradation by renal dehydropeptidase-1 and binds penicillin-binding proteins with high affinity, while sulbactam neutralizes beta-lactamases and exerts direct bactericidal activity against Acinetobacter baumannii. Indicated for life-threatening nosocomial infections, ventilator-associated pneumonia, septicemia, complicated intra-abdominal infections, and severe surgical sepsis caused by MDR pathogens.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.